Latest News & Features
Refine search
Asia
The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar. 31 March 2026
Europe
Judges found no reason to set aside provisional measures issued by a local division, following a challenge from Sinocare and A Menarini Diagnostics. 30 March 2026
Americas
A long-running patent clash over gene editing returns to a fundamental question, as a US court takes another look at the evidence. 30 March 2026
Biotechnology
The Swiss pharma giant targets next-generation anti-IgE biologics as it looks to extend its dominance in the market. 27 March 2026
Europe
LSIPR sister title launches vetted list celebrating leading in-house counsel who demonstrate exceptional ability in managing their organisation's IP portfolio, legal team, and IP culture. 26 March 2026
Biotechnology
As the world moves past the pandemic, a massive legal struggle over the future of mRNA technology is just hitting its stride. LSIPR visualises the litigation defining the next era. 25 March 2026
Careers
Two senior hires from a rival firm bring litigation expertise across life sciences and tech disputes. 25 March 2026
Europe
The drugmaker’s attempt to extend protection for a fast-growing oestrogen-free contraceptive ran into a landmark EU ruling, with the court not persuaded to read it narrowly. 24 March 2026
Europe
The European Patent Office’s Technology Dashboard reveals only a slight increase in medtech filings, and drops in biotech and pharma, against an overall healthy backdrop. 24 March 2026
Big Pharma
With Novo Nordisk's core semaglutide patent expired in India last week, the company that built one of the most successful drugs in pharmaceutical history is already fighting on a new front. So what comes next? 23 March 2026


